Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma

Leukemia Research

Volumn 25, Issue 1, 2001, Pages 95-98

  Misgeld, Ernst ^a   Germing, Ulrich ^a   Aul, Carlo ^b   Gattermann, Norbert ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOHANNES HOSPITAL   (Germany)

Author keywords

CHOP chemotherapy; Fludarabine; Myelodysplastic syndrome; Non Hodgkin's lymphoma; Rituximab; Secondary neoplasia; Therapy related

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; VINCRISTINE SULFATE;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; FATALITY; FEMALE; HUMAN; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LOW-GRADE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; VIDARABINE;

EID: 0035183056     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00092-8     Document Type: Article

References (23)

1. Overall evaluations of carcinogenicity: An updating of IARC Monographs volumes 1 to 42
2. Myelodysplastische syndrome
3. Chromosome abnormalities in secondary myelodysplastic syndromes
4. Secondary myelodysplastic syndromes (MDS)
5. Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome
6. Long term follow-up and late complications of 2-Chlorodeoxyadenosine in previously treated, advanced, indolent non Hodgkin's lymphoma
7. Translocations (5;17) and (7;17) in patients with de novo or therapy-related myelodysplastic syndromes or acute nonlymphocytic leukemia. A possible association with acquired pseudo-Pelger-Huet anomaly and small vacuolated granulocytes
8. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia
9. Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy
10. Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treating with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage
11. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure
12. Therapy-related myelodysplastic syndrome (T-MDS) or acute myeloid leukemia (T-AML) in patients with chronic lymphocytic leukemia (CLL) treated with Chlorambucil (C), Fludarabine (F), or Fludarabine+Chlorambucil (F+C): An intergroup study (Cancer and Leukemia Group B (CALGB) 9011)
13. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2-deoxyadenosine
14. Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders
15. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment
16. Translocation (3;21)(q26,q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation
17. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II
18. Chromosome aberrations and prognostic factors in the therapy-related myelodysplasia and acute nonlymphocytic leukemia
19. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
20. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia
21. t(3;21)(q26;q22): A recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia
22. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II